CIK 0001811063 · Non-accelerated filer<br>Smaller reporting company
Nuvation Bio Inc.
Sign in to watch- Ticker
- NUVB
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 850862255
- Phone
- 332-208-6102
- Business address
- 1 PENNSYLVANIA PLAZA, SUITE 3805, NEW YORK, NY, 10019
- Former names
- Panacea Acquisition Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $709,240
- in 1 filing, $709K under 10b5-1 plans
Net −$709,240. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-29 | Hung David PRESIDENT AND CEO | Grant or award · Stock Option (Right to Buy) | +2,000,000 | 2,000,000 | ||
| 2024-01-08 | Mashal Robert Director | Grant or award · Stock Option (Right to Buy) | +741,179 | 741,179 | ||
| 2023-09-21 | NODELMAN OLEG Director | Purchase | +53,000 | $1.36 | $72K | 12,674,775 |
| 2023-09-20 | NODELMAN OLEG Director | Purchase | +117,100 | $1.36 | $159K | 12,621,775 |
| 2023-09-19 | NODELMAN OLEG Director | Purchase | +5,143,000 | $1.26 | $6.5M | 12,504,675 |
| 2023-05-15 | WELCH DANIEL G Director | Grant or award · Stock Option (Right to Buy) | +366,744 | 366,744 | ||
| 2023-05-15 | VERNON W ANTHONY Director | Grant or award · Stock Option (Right to Buy) | +366,744 | 366,744 | ||
| 2023-05-15 | FALBERG KATHRYN E Director | Grant or award · Stock Option (Right to Buy) | +366,744 | 366,744 | ||
| 2023-05-15 | BLICKENSTAFF KIM D Director | Grant or award · Stock Option (Right to Buy) | +366,744 | 366,744 | ||
| 2023-05-15 | Bazemore Robert B Director | Grant or award · Stock Option (Right to Buy) | +366,744 | 366,744 | ||
| 2023-02-28 | Markel Stacy Chief People Officer | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2023-02-28 | Hung David President and CEO | Grant or award · Stock Option (Right to Buy) | +2,500,000 | 2,500,000 | ||
| 2023-02-28 | Hanley David C. Chief Technical Operations | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2023-02-28 | Fox Jennifer A. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +600,000 | 600,000 | ||
| 2023-02-28 | Wentworth Kerry Chief Regulatory Officer | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2023-02-28 | Liu Dongfang Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2023-02-28 | Hattersley Gary Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2023-02-21 | NODELMAN OLEG Director | Purchase | +53,000 | $1.36 | $72K | 12,674,775 |
| 2023-02-20 | NODELMAN OLEG Director | Purchase | +117,100 | $1.36 | $159K | 12,621,775 |
| 2023-02-19 | NODELMAN OLEG Director | Purchase | +5,143,000 | $1.26 | $6.5M | 12,504,675 |
Page 9 of 15 · 291 trades